TY - JOUR T1 - Assessing treatment tolerability for rheumatoid arthritis. Validation and practical applications of the ‘TOL-AR-18 questionnaire’ JO - Reumatología Clínica T2 - AU - Corominas,Hèctor AU - Espadaler,Luís AU - Gómez,Antoni AU - Ros,Inmaculada AU - Urruticoechea,Ana AU - Sarmiento,Mònica AU - Sanmartí,Raimon SN - 1699258X M3 - 10.1016/j.reuma.2018.06.005 DO - 10.1016/j.reuma.2018.06.005 UR - https://reumatologiaclinica.org/es-assessing-treatment-tolerability-for-rheumatoid-articulo-S1699258X18301232 AB - IntroductionGiven the lack of standardized tools to assess tolerability from patient's perspective, we carried out the validation of a questionnaire to asses treatment tolerability for rheumatoid arthritis (RA): TOL-AR-18. MethodsThe TOL-AR-18 was validated in the cross-sectional observational study in adult patients with RA. Socio-demographic and clinical variables were collected. Patients completed the TOL-AR-18 and ARTS questionnaires and a question about their general health status. ResultsData of 66 patients with a mean age (standard deviation; SD) of 56.71 (10.50) years were analyzed; 66.7% were women. Mean (SD) time to disease progression was 10.76 (8.23) years, and time from first treatment initiation was 9.24 (7.70) years. Patients did not report other adverse events rather than those included in the TOL-AR-18. The questionnaire was feasible with high internal consistency (Cronbach's α >0.90). Discriminant validity was moderate, with significant differences between patients in remission and all other, and between patients who did not report adverse events and the rest (P<.05). Convergent validity was moderate–low when correlated with the ARTS questionnaire. ConclusionThe TOL-AR-18 is valid for use in a clinical setting and useful as an additional tool for all professionals to manage and assess tolerability in RA. ER -